Mostrando ítems 31-40 de 68
HTLV-1 infection and health outcomes
(The Lancet Infectious Diseases, 2020-04)
The meta-analysis published by Gill Schierhout and colleagues1 reported an increased relative risk of premature death in individuals infected with HTLV-1 compared with individuals not infected with HTLV-1 (RR 1·57, 95% CI ...
Hepatitis Delta Estimates in the United States Revisited
(Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019-10-30)
To the Editor—We read with interest the article by Patel and colleagues , which reported an unexpected 33% prevalence of anti–hepatitis delta virus antibodies (anti-HDV-Abs) in a large and representative US household ...
Tough requirements for new antiretroviral drugs
(The Lancet HIV, 2020-03)
Medical and social attention to HIV infection has declined globally and is increasingly focused on developing regions, where the epidemic is still largely uncontrolled. In North America and western Europe, AIDS is rarely ...
HTLV testing of solid organ transplant donors
(Clinical Transplantation, 2019)
Carta al editor
Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2
(Journal of Infectious Diseases, 2020-06)
Background: HIV-1 and HIV-2 differ in their antiretroviral (ARV) susceptibilities and drug resistance mutations (DRMs). Methods: We analyzed published HIV-2 pol sequences to identify HIV-2 treatment-selected mutations ...
Hospital admissions in individuals with HTLV-1 infection in Spain
OBJECTIVE: To examine the clinical burden and disease spectrum, as well as time trends for human T-cell leukemia virus type 1 (HTLV-1) and HTLV type 2 (HTLV-2) hospital admissions. DESIGN: Retrospective, observational study ...
Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity
(International Journal of Infectious Diseases, 2020-08)
A relationship between the infecting dose and the risk of disease severity has not been demonstrated for SARS-CoV-2 infection. Here, we report three clusters of individuals that were potentially exposed to distinct inoculum ...
Long-acting antiretroviral therapy
(Nature Materials, 2020-08-01)
Nanoformulations of cabotegravir prodrugs have been developed to prolong the pharmacokinetics of the antiretroviral agent. They can be present in the plasma of mice and non-human primates for a year following a single injection.
Advances in hepatitis B therapeutics
(Therapeutic Advances in Infectious Disease, 2020-10)
Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of ...
Overt and occult hepatitis B among immigrants and native blood donors in Madrid, Spain
(Therapeutic Advances in Infectious Disease, 2020-12)
Background: The risk of transfusion-transmitted viral infections is very low in developed countries. Recent massive migration flows from highly hepatitis B virus (HBV), hepatitis C virus (HCV) and/or HIV endemic regions ...